CSIMarket
 


Immune Design Corp.  (IMDZ)
Other Ticker:  
 
 

IMDZ's Revenue Growth by Quarter and Year

Immune Design.'s Revenue results by quarter and year




IMDZ Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December 0.94 0.49 2.06 1.14
III Quarter September 0.46 0.52 8.21 4.65
II Quarter June 0.76 0.73 1.13 1.78
I Quarter March 0.50 5.47 1.86 1.94
FY   2.66 7.21 13.26 9.51



IMDZ Revenue fourth quarter 2018 Y/Y Growth Comment
Immune Design Corp. achieved in the fourth quarter 2018, above Company average Revenue rise of 91.43% year on year, to $ 0.94 millions.

Looking into fourth quarter 2018 results within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Revenue growth. While Immune Design Corp.' s Revenue jump of 91.43% ranks overall at the positon no. 341 in the fourth quarter 2018.




IMDZ Revenue ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December 91.43 % -76.21 % 80.7 % -
III Quarter September -11.54 % -93.67 % 76.56 % 31.36 %
II Quarter June 4.11 % -35.4 % -36.52 % 67.92 %
I Quarter March -90.86 % 194.09 % -4.12 % -
FY   -63.13 % -45.63 % 39.43 % -

Financial Statements
Immune Design.'s fourth quarter 2018 Revenue $ 0.94 millions IMDZ's Income Statement
Immune Design.'s fourth quarter 2017 Revenue $ 0.49 millions Quarterly IMDZ's Income Statement
New: More IMDZ's historic Revenue Growth >>


IMDZ Revenue (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December 103.91 % -5.77 % -74.91 % -75.48 %
III Quarter September -39.47 % -28.77 % 626.55 % 161.24 %
II Quarter June 52 % -86.65 % -39.25 % -8.25 %
I Quarter March 2.04 % 165.53 % 63.16 % -
FY (Year on Year)   -63.13 % -45.63 % 39.43 % -




Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #83
Overall #341

Revenue Y/Y Growth Statistics
High Average Low
193.34 % 14.19 % -93.71 %
(Mar 31 2017)   (Sep 30 2017)
Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #83
Overall #341
Revenue Y/Y Growth Statistics
High Average Low
193.34 % 14.19 % -93.71 %
(Mar 31 2017)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Immune Design.'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
624.27 % 65.39 % -86.66 %
(Sep 30 2016)  


IMDZ's IV. Quarter Q/Q Revenue Comment
Immune Design Corp. achieved in the IV. Quarter 2018 above company average sequential Revenue doubling of 103.91%, to $ 0.94 millions, from $0.46 millions in the third quarter.
Immune Design. is undergoing a remarkable growth, with reporting above normal gain, and also improving pace.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Immune Design.'s Revenue growth quarter on quarter, overall rank is 231.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #67
Overall #231
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #67
Overall #231
Revenue Q/Q Growth Statistics
High Average Low
624.27 % 65.39 % -86.66 %
(Sep 30 2016)  


IMDZ's IV. Quarter Q/Q Revenue Comment
Immune Design Corp. achieved in the IV. Quarter 2018 above company average sequential Revenue doubling of 103.91%, to $ 0.94 millions, from $0.46 millions in the third quarter.
IMDZ is impressively improving, not just recording better then regular gain, but also accelerating pace, David Taylor, market advisor said.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Immune Design.'s Revenue growth quarter on quarter, overall rank is 231.


Immune Design.'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
Cumulative Revenue 12 Months Ending $ 2.66 $ 2.21 $ 2.26 $ 2.23 $ 7.20
Y / Y Revenue Growth (TTM) -63.06 % -74.85 % -86.27 % -86.76 % -45.74 %
Year on Year Revenue Growth Overall Ranking # 3787 # 0 # 767 # 1122 # 552
Seqeuential Revenue Change (TTM) 20.54 % -2.39 % 1.16 % -68.96 % -17.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 3505 # 0 # 516 # 3872 # 2019




Cumulative Revenue growth Comment
Immune Design. showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2018. If the fiscal year would end in Dec 31 2018, Immune Design.'s annual Revenue fall would be -63.06% year on year to $3 millions.

In the Healthcare sector 472 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3787.

Revenue TTM Q/Q Growth Statistics
High Average Low
386.84 %
55.48 %
-86.76 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 155
Healthcare Sector # 473
Overall # 3787

Revenue TTM Y/Y Growth Statistics
High Average Low
386.84 %
66.25 %
-86.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 155
Sector # 416
S&P 500 # 3505
Cumulative Revenue growth Comment
Immune Design. showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2018. If the fiscal year would end in Dec 31 2018, Immune Design.'s annual Revenue drop would be -63.06% year on year to $3 millions.

In the Healthcare sector 472 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3787.

Revenue TTM Q/Q Growth Statistics
High Average Low
386.84 %
55.48 %
-86.76 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 155
Healthcare Sector # 473
Overall # 3787

Revenue TTM Y/Y Growth Statistics
High Average Low
386.84 %
66.25 %
-86.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 155
Sector # 416
S&P 500 # 3505




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IMDZ's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for IMDZ's Competitors
Revenue Growth for Immune Design.'s Suppliers
Revenue Growth for IMDZ's Customers

You may also want to know
IMDZ's Annual Growth Rates IMDZ's Profitability Ratios IMDZ's Asset Turnover Ratio IMDZ's Dividend Growth
IMDZ's Roe IMDZ's Valuation Ratios IMDZ's Financial Strength Ratios IMDZ's Dividend Payout Ratio
IMDZ's Roa IMDZ's Inventory Turnover Ratio IMDZ's Growth Rates IMDZ's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Dec 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2018
Cardiff Lexington Corporation159.98%$ 159.977 millions
Edesa Biotech Inc 158.86%$ 158.862 millions
Fibrogen Inc 154.20%$ 154.197 millions
Ladrx Corporation150.00%$ 150.000 millions
Veru Inc 146.34%$ 146.338 millions
Myokardia Inc 138.47%$ 138.471 millions
H cyte Inc136.52%$ 136.524 millions
Aceragen Inc 135.26%$ 135.260 millions
Reflect Scientific Inc 132.89%$ 132.893 millions
Trinity Biotech Plc131.64%$ 131.642 millions
Avalo Therapeutics Inc 123.15%$ 123.148 millions
Amicus Therapeutics inc 121.63%$ 121.631 millions
Asensus Surgical Inc 121.42%$ 121.424 millions
Davita Inc 115.44%$ 115.445 millions
Teladoc Health Inc 113.97%$ 113.966 millions
Universal Health Services Inc 109.74%$ 109.737 millions
Heron Therapeutics Inc 102.28%$ 102.279 millions
Imunon Inc 100.00%$ 100.000 millions
Innovage Holding Corp 99.76%$ 99.757 millions
Neos Therapeutics Inc 97.68%$ 97.676 millions
Sarepta Therapeutics Inc 95.52%$ 95.524 millions
Immune Design Corp.93.40%$ 93.402 millions
Vivus Inc92.69%$ 92.689 millions
Exelixis Inc 91.53%$ 91.531 millions
Caredx Inc 88.03%$ 88.027 millions
Ontrak Inc 85.30%$ 85.305 millions
Wave Life Sciences Ltd 84.69%$ 84.694 millions
Dicerna Pharmaceuticals Inc 84.20%$ 84.203 millions
Enanta Pharmaceuticals Inc83.38%$ 83.385 millions
Precision Optics Corporation Inc 81.83%$ 81.828 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com